B. Nelson

University of Cincinnati — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

8h-index9.0kcitations19works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(7), Cancer Immunotherapy and Biomarkers(6), Bladder and Urothelial Cancer Treatments(6), Urinary and Genital Oncology Studies(5), Computational Drug Discovery Methods(3)

Publications19 total

Gender and the Receipt of the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award
International Journal of Radiation Oncology*Biology*Physics·2023Open Access
699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
Annals of Oncology·2021· 7 cited
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial
European Urology·2021· 116 cited
Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study
Annals of Oncology·2019· 6 citedOpen Access
Corrigendum re: “Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens” [Eur Urol 2018;73:462–8]
European Urology·2018
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
European Urology·2017· 50 citedOpen Access
1143 A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010)
European Urology Supplements·2016· 3 cited
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
The Oncologist·2013· 213 citedOpen Access
PO-46: CTLA-4 Blockade with Androgen Deprivation and Radiotherapy for the Treatment of Prostate Cancer
Radiotherapy and Oncology·2012
Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial
European Journal of Cancer·2011· 4 cited
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with <sup>V600E</sup>BRAF-mutated melanoma.
Journal of Clinical Oncology·2011· 26 cited
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
New England Journal of Medicine·2011· 7.6k citedOpen Access
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas.
Journal of Clinical Oncology·2011· 2 cited
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma (ASCO 2011 Melanoma, Abstract LBA4)
Research Explorer (The University of Manchester)·2011
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma
2011· 13 cited
Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial
Journal of Clinical Oncology·2005· 932 citedOpen Access
Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer
Journal of Clinical Oncology·2004· 12 cited
INVESTIGATIONS OF CARBOXY-HEMOGLOBIN OF ADULT SMOKERS OF CONVENTIONAL CIGARETTES AND AN ELECTRICALLY HEATED CIGARETTE.(GENERAL SESSION BY POSTER PRESENTATION)(ENVIRONMENTAL CHEMICALS,HEAVY METALS & CYTOTOXICITY)
The Journal of Toxicological Sciences·2002
OCCUPATIONAL THERAPY WITH EARLY SCHIZOPHRENICS IN AN OUT-PATIENT CLINIC OF A GENERAL HOSPITAL
American Journal of Physical Medicine & Rehabilitation·1937

Frequent Co-authors

Axel Hauschild(7), Caroline Robert(7), K. B. Nolop(7), Paul B. Chapman(6), Paolo A. Ascierto(6), Grant A. McArthur(6), James Larkin(5), Reinhard Dummer(5), Claus Garbe(5), Alessandro Testori(5), David Hogg(5), Paul Lorigan(5), Steven O’Day(5), Jeannie Hou(5), Keith T. Flaherty(5), Michiel S. van der Heijden(5), Yohann Loriot(5), Thomas Powles(5), Ignacio Durán(4), Margitta Retz(4)